UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of June 2020

 

Commission File Number: 001-37353

 

BIONDVAX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

 

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jeusalem, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

On June 10, 2020, BiondVax Pharmaceuticals Ltd. issued a press release announcing NIH completion of report on Phase 2 clinical trial of BiondVax’s M-001 universal influenza vaccine candidate concluding both primary endpoints achieved.

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Press Release dated June 10, 2020

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BiondVax Pharmaceuticals Ltd.
     
Date: June 10, 2020 By: /s/ Ron Babecoff
    Ron Babecoff
    Chief Executive Officer

 

2

 

BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more BiondVax Pharmaceuticals Charts.
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more BiondVax Pharmaceuticals Charts.